GlobeNewswire Inc | Sep 3, 2021 07:00AM EDT

September 03, 2021

NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference.

Renalytixs management is scheduled to participate in a fireside chat Friday, September 10 at 2:40 p.m. EDT. Interested parties may access a live and archived webcast of the presentation on the Investors section of the company website at investors.renalytix.com.

About RenalytixRenalytix (LSE: RENX) (NASDAQ: RNLX) Renalytix is the global founder and leader in the new field of bioprognosisfor kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Companys lead product is KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visitwww.kidneyintelx.com). For more information, visitwww.renalytix.com.

UK Investor Contact:

Walbrook PRLimited Tel: 020 7933 8780or renalytix@walbrookpr.comPaul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303

US Investor Contact:

CapComm Partners investors@renalytix.comPeter DeNardo 415-389-6400